The optimal efficacy of pembrolizumab was observed in treated NSCLC patients with PD-L1 expression in at least 50% of tumor cells, revealing the predictive value of PD-L1 expression as a biomarker10,11. The gene discussed is CD274; the disease is neoplasm.